Shenyang Xingqi Pharmaceutical Co Ltd (SHE:300573) — Market Cap & Net Worth

$2.50 Billion USD  · CN¥17.11 Billion CNY  · Rank #5484

Market Cap & Net Worth: Shenyang Xingqi Pharmaceutical Co Ltd (300573)

Shenyang Xingqi Pharmaceutical Co Ltd (SHE:300573) has a market capitalization of $2.50 Billion (CN¥17.11 Billion) as of May 3, 2026. Listed on the SHE stock exchange, this China-based company holds position #5484 globally and #1113 in its home market, demonstrating a 1.31% increase in market value over the past year.

Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shenyang Xingqi Pharmaceutical Co Ltd's stock price CN¥69.45 by its total outstanding shares 246429527 (246.43 Million). Analyse 300573 cash flow conversion to see how efficiently the company converts income to cash.

Shenyang Xingqi Pharmaceutical Co Ltd Market Cap History: 2016 to 2026

Shenyang Xingqi Pharmaceutical Co Ltd's market capitalization history from 2016 to 2026. Data shows growth from $588.42 Million to $2.50 Billion (37.23% CAGR).

Index Memberships

Shenyang Xingqi Pharmaceutical Co Ltd is a constituent of 1 market index:

Index Total Market Cap Weight (%) Rank by Market Cap
ChiNext
CNT
$1.31 Trillion 0.19% #81 of 100

Weight: Shenyang Xingqi Pharmaceutical Co Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.

Shenyang Xingqi Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline

This chart shows how Shenyang Xingqi Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.

Latest Price to Sales (P/S) Ratio

1.29x

Shenyang Xingqi Pharmaceutical Co Ltd's market cap is 1.29 times its annual revenue

Industry average: 0.98x Higher than industry average

Latest Price to Earnings (P/E) Ratio

7.44x

Shenyang Xingqi Pharmaceutical Co Ltd's market cap is 7.44 times its annual earnings

Industry average: 1342.12x Lower than industry average

What These Ratios Tell Investors:

  • Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
  • Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
  • Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
  • Industry comparison provides context for whether the company is valued higher or lower than peers.
Year Market Cap (USD) Revenue (USD) Net Income (USD) P/S Ratio P/E Ratio
2016 $588.42 Million $339.10 Million $54.28 Million 1.74x 10.84x
2017 $428.74 Million $360.01 Million $39.44 Million 1.19x 10.87x
2018 $293.89 Million $431.20 Million $13.66 Million 0.68x 21.52x
2019 $1.29 Billion $542.43 Million $35.89 Million 2.38x 35.91x
2020 $1.68 Billion $688.68 Million $87.98 Million 2.43x 19.04x
2021 $2.42 Billion $1.03 Billion $194.70 Million 2.35x 12.40x
2022 $2.23 Billion $1.25 Billion $211.68 Million 1.78x 10.53x
2023 $4.60 Billion $1.47 Billion $240.04 Million 3.13x 19.16x
2024 $2.52 Billion $1.94 Billion $338.06 Million 1.29x 7.44x

Competitor Companies of 300573 by Market Capitalization

Companies near Shenyang Xingqi Pharmaceutical Co Ltd in the global market cap rankings as of May 3, 2026.

Key companies related to Shenyang Xingqi Pharmaceutical Co Ltd by market ranking:

  • Intuitive Surgical Inc (NASDAQ:ISRG): Ranked #136 globally with a market cap of $162.57 Billion USD.
  • EssilorLuxottica S. A. (PA:EL): Ranked #250 globally with a market cap of $98.12 Billion USD ( €83.93 Billion EUR).
  • ESSILORLUXOTTICA 1/2/O.N. (F:ESLC): Ranked #274 globally with a market cap of $93.24 Billion USD ( €79.76 Billion EUR).
  • HOYA CORP. ADR/ 1 O.N. (F:HYB0): Ranked #523 globally with a market cap of $50.37 Billion USD ( €43.09 Billion EUR).
Market capitalization comparison (in billions USD)
Rank Company Symbol Market Cap Price
#136 Intuitive Surgical Inc NASDAQ:ISRG $162.57 Billion $457.78
#250 EssilorLuxottica S. A. PA:EL $98.12 Billion €181.25
#274 ESSILORLUXOTTICA 1/2/O.N. F:ESLC $93.24 Billion €88.50
#523 HOYA CORP. ADR/ 1 O.N. F:HYB0 $50.37 Billion €150.00

Shenyang Xingqi Pharmaceutical Co Ltd Historical Marketcap From 2016 to 2026

Between 2016 and today, Shenyang Xingqi Pharmaceutical Co Ltd's market cap moved from $588.42 Million to $ 2.50 Billion, with a yearly change of 37.23%.

Year Market Cap Change (%)
2026 CN¥2.50 Billion -1.20%
2025 CN¥2.53 Billion +0.73%
2024 CN¥2.52 Billion -45.29%
2023 CN¥4.60 Billion +106.39%
2022 CN¥2.23 Billion -7.72%
2021 CN¥2.42 Billion +44.17%
2020 CN¥1.68 Billion +29.96%
2019 CN¥1.29 Billion +338.61%
2018 CN¥293.89 Million -31.45%
2017 CN¥428.74 Million -27.14%
2016 CN¥588.42 Million --

End of Day Market Cap According to Different Sources

On May 3rd, 2026 the market cap of Shenyang Xingqi Pharmaceutical Co Ltd was reported to be:

Source Market Cap
Yahoo Finance $2.50 Billion USD
MoneyControl $2.50 Billion USD
MarketWatch $2.50 Billion USD
marketcap.company $2.50 Billion USD
Reuters $2.50 Billion USD

Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.

About Shenyang Xingqi Pharmaceutical Co Ltd

SHE:300573 China Medical Instruments & Supplies
Market Cap
$2.50 Billion
CN¥17.11 Billion CNY
Market Cap Rank
#5484 Global
#1113 in China
Share Price
CN¥69.45
Change (1 day)
-1.29%
52-Week Range
CN¥50.31 - CN¥83.32
All Time High
CN¥204.82
About

Shenyang Xingqi Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of ophthalmic medications in the People's Republic of China. The company provides myopia prevention and control medications, nutrition and corneal repair drugs, ophthalmic anti-inflammatory/anti-infective drugs, artificial tears and eye lubricants, ophthalmic non-steroidal anti-inflammatory drugs… Read more